Avadel pharmaceuticals announces interim data from the open-label restore study at the 2022 american academy of neurology annual meeting

Dublin, ireland, april 25, 2022 (globe newswire) -- avadel pharmaceuticals plc (nasdaq: avdl), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the presentation of interim data from the ongoing restore open-label extension/switch study of ft218 at the 2022 american academy of neurology annual (aan) meeting being held virtually from april 24-26, 2022. ft218 is the company's lead drug candidate, an investigational formulation of sodium oxybate designed to be taken once at bedtime for the treatment of excessive daytime sleepiness (eds) or cataplexy in adults with narcolepsy. the presentation highlights results from a questionnaire assessing patient preference for the once-nightly versus twice-nightly dosing regimen and another questionnaire assessing experiences with the second nightly dose in patients who switched from twice-nightly oxybates to ft218.
AVDL Ratings Summary
AVDL Quant Ranking